دانلود کتاب Interaction of Coronavirus Disease 2019 with other Infectious and Systemic Diseases [Team-IRA]

فهرست مطالب :

Cover
Half Title
Title
Copyright
Contents
List of Contributors
Part I Current Trends in Pathophysiology and Post-COVID Effects
Chapter 1 Pathophysiology of SARS-CoV-2
1.1 Introduction
1.2 Structure of the Virus
1.3 Entry of SARS-CoV-2
1.4 Entry Factors of SARS-CoV2
1.5 Hallmark of COVID-19
1.5.1 Pathophysiology of SARS-CoV-2
1.6 Affecting Respiratory Tract
1.7 SARS-CoV-2 Infection Affects RAAS
1.8 Endothelial Dysfunction and Platelet Activation
1.9 Endocrine Dysfunction
1.9.1 Neuropathology
1.10 List of Abbreviations
Acknowledgement
References
Chapter 2 Investigation of Post-COVID/Long COVID Complications in Humans
2.1 Introduction
2.2 Pathophysiology
2.3 Respiratory Complications
2.4 Cardiovascular Complexities
2.5 Haematological Abnormalities
2.6 Neurological Complications
2.7 Dermatological Sequelae
2.8 Diabetes-Related Comorbidities
2.9 Renal Complications
2.10 Gastrointestinal Sequelae
2.11 Conclusion
References
Part II SARS CoV-2 Co-Infection with Other Pathogens
Chapter 3 Falciparum Malaria and COVID-19 Co-Infections
3.1 Introduction
3.2 Interactions Between SARS-CoV-2 Infection and Malaria
3.3 Similarity of Malaria and COVID-19 Symptoms and Problems Associated with It
3.4 Potential Effects of Previous Malaria Exposure on Clinical Profiles and Outcomes in Patients with SARS-CoV-2 Infection
3.5 Important Clinical Correlations of Co-Infection in High Malaria Burden Areas
3.6 Conclusion
References
Chapter 4 Interaction of COVID-19 and Tuberculosis
4.1 Introduction
4.2 Epidemiological and Clinical Presentation of COVID-19 with TB Infection
4.3 Biological Mechanism of COVID-19 and TB
4.4 Diagnostic Approaches for COVID-19 and Tuberculosis
4.4.1 Diagnostic Approaches for COVID-19
4.4.2 Smear Microscopy using Ziehl Neelsen (ZN) Staining Method
4.5 Impact of COVID-19 on TB
4.6 Conclusion
References
Chapter 5 Coinfection of SARS-CoV-2 with Viruses Causing Respiratory and Systemic Infections
5.1 Introduction
5.2 Respiratory Viral Co-Infection in COVID-19
5.2.1 Co-Infection of SARS-CoV-2 with Influenza Virus
5.2.2 Co-Infection of SARS-CoV-2 with Human Coronavirus (CoVs)
5.2.3 Co-Infection of SARS-CoV-2 with Adenovirus
5.3 Systemic Viral Co-Infection in COVID-19
5.3.1 SARS-CoV-2 and HIV Co-Infections
5.3.2 SARS-CoV-2 and CMV Co-Infections
5.3.3 SARS-CoV-2 and EBV Co-Infections
5.3.4 SARS-CoV-2 and HBV Co-Infections
5.4 Viral Co-infections: Symptoms and Diagnosis
5.5 Conclusion
References
Part III COVID-19 and Neurological Complications
Chapter 6 Neurological Association of COVID-19 and Neurodegenerative Disorders
6.1 Introduction
6.2 COVID-19 and Neurodegenerative Diseases
6.3 COVID-19 and AD
6.4 COVID-19 and PD
6.5 COVID-19 and MS
6.6 Major Association of COVID-19 and PD
6.7 Receptors Involved in COVID-19 and PD
6.8 Redox Homeostasis and Inflammatory Responses in COVID-19 and PD
6.9 Sensory Traits in COVID-19 and PD
6.10 Metabolic and Psychiatric Sickness in COVID-19 and PD
6.11 Concluding Remarks
References
Part IV COVID-19 and Cancer
Chapter 7 Immuno-Oncological Challenge of COVID-19 in Cancer Care and Prognosis
7.1 Introduction
7.2 Hallmarks of Cancer and COVID-19
7.3 Genetics of Cancer and COVID-19
7.4 Immuno-Oncological Interaction in Cancer During Coronavirus Infection
7.5 Oxidative Stress and Chronic Inflammation in Cancer During Coronavirus Infection
7.6 Impact of COVID-19 on Treatment of Cancer
7.7 Prognosis and Preventive Approaches for Cancer and COVID-19
7.8 Conclusion
Acknowledgements
References
Chapter 8 COVID-19 Severity in Lung Cancer Patients and Current Treatment
8.1 Introduction
8.2 Impact of Lung Cancer and COPD on the Severity of COVID-19
8.3 Prevalence, Diagnosis, Management and Prevention of COVID-19 in Lung Cancer or COPD
8.3.1 Prevalence
8.3.2 Diagnosis
8.3.3 Management
8.3.4 Prevention
8.4 Challenges for Access to Care for COVID-19 Patients with Lung Cancer or COPD
8.5 Conclusion
Acknowledgement
References
Part V Current Therapeutic Approaches
Chapter 9 COVID-19 Therapy: Molecular Mechanisms, Pharmacological Interventions and Therapeutic Targets
9.1 Introduction
9.2 Genetic Structure and Pathogenesis of CoVs
9.3 Structure Based Drug Targets of SARS-CoV-2
9.4 Potential Treatment Options of SARS-CoV-2
9.4.1 Convalescent Plasma Therapy
9.4.2 Monoclonal Antibody-Based Therapy
9.4.3 Antibody-Based Treatment of SARS-CoV-2
9.4.4 Targeting of Alternative Pathways for the Treatment of SARS-CoV-2
9.5 Currently Used Therapeutic Strategies for Treatment SARS-CoV-2
9.5.1 Treatment Based on Drugs
9.5.2 Anti-Malarial Drugs
9.5.3 Antiviral Drugs
9.5.4 Other Category Drugs
9.5.5 Nutritional Supplements
9.5.6 Use of Disinfectants and Soaps
9.5.7 Vaccines Against SARS-CoV-2
9.6 Conclusion
9.7 Declaration of Competing Interest
Acknowledgements
References
Chapter 10 Exploration of Nanotherapeutics in COVID-19
10.1 Introduction
10.2 Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
10.3 Infection
10.4 Nanotherapy
10.5 Application of Nanotherapy in COVID-19 Management
10.6 Nano Vaccine
10.7 Surface Disinfection
10.8 Personal Protective Equipment (PPE)
10.9 Nanodiagnostics
10.10 Nanobiosensors
10.11 Nanomaterial Based Smart Phone Detectors
10.12 Nanotheranostics
10.13 Applications Using Inorganic and Organic Particles
10.14 Nano Biomaterials
10.15 Regulatory Aspects of Nanoparticles
10.16 Limitations
10.17 Conclusion
References
Chapter 11 Pharmacogenomics and COVID-19
11.1 Introduction
11.2 A Detailed Overview of Pharmacogenomics (PGx)
11.3 Gene Polymorphism and Pharmacogenomic Research
11.4 Pharmacogenomics of Anti-COVID-19 Drugs
11.4.1 Chloroquine and Hydroxychloroquine
11.4.2 Lopinavir and Ritonavir
11.4.3 Azithromycin
11.4.4 Corticosteroids
11.4.5 Renin–Angiotensin–Aldosterone System (RAAS) Inhibitors
11.4.6 Janus Kinase (JAK) Inhibitors
11.5 Concluding Remarks
11.6 Conflict of Interest
References
Index